Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: A single center study

BACKGROUND: KRAS mutations negatively affect outcome after treatment with cetuximab in metastatic colorectal cancer (mCRC) patients. As only 20% of KRAS wild type (WT) patients respond to cetuximab it is possible that other mutations, constitutively activating the EGFR pathway, are present in the no...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Ulivi, Paola, Capelli, Laura, Valgiusti, Martina, Zoli, Wainer, Scarpi, Emanuela, Chiadini, Elisa, Rosetti, Paola, Bravaccini, Sara, Calistri, Daniele, Saragoni, Luca, Casadei Gardini, Andrea, Ragazzini, Angela, Frassineti, Giovanni Luca, Amadori, Dino, Passardi, Alessandro
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2012
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3404915/
https://ncbi.nlm.nih.gov/pubmed/22569004
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-10-87
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars